Chronic Lymphocytic Leukemia News and Research

RSS
Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.
New integrative NGS panel for analysis of standard and novel biomarkers in lymphoid neoplasms

New integrative NGS panel for analysis of standard and novel biomarkers in lymphoid neoplasms

Oral targeted therapy found to be an effective treatment option for high-risk hairy cell leukemia

Oral targeted therapy found to be an effective treatment option for high-risk hairy cell leukemia

Protein markers in chronic lymphocytic leukemia may help determine patients' prognoses

Protein markers in chronic lymphocytic leukemia may help determine patients' prognoses

Maternal Omega 3-rich diet may reduce onset of breast cancer in offspring

Maternal Omega 3-rich diet may reduce onset of breast cancer in offspring

Can convalescent plasma therapy improve COVID-19 outcomes in patients with hematologic cancers?

Can convalescent plasma therapy improve COVID-19 outcomes in patients with hematologic cancers?

Extensive cancer research data to be presented at the 2021 ASCO Annual Meeting

Extensive cancer research data to be presented at the 2021 ASCO Annual Meeting

Machine learning technique detects epigenetic drivers of cancers

Machine learning technique detects epigenetic drivers of cancers

New NCCN patient guidelines on anemia and neutropenia published

New NCCN patient guidelines on anemia and neutropenia published

Yale scientists uncover common mechanism that promotes autoimmune diseases and blood cancers

Yale scientists uncover common mechanism that promotes autoimmune diseases and blood cancers

Studies suggest mRNA COVID-19 vaccine may have reduced efficacy in patients with blood cancer

Studies suggest mRNA COVID-19 vaccine may have reduced efficacy in patients with blood cancer

New recipients for the 2021 NCCN Foundation Young Investigator Awards announced

New recipients for the 2021 NCCN Foundation Young Investigator Awards announced

Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas

Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas

If I have cancer, dementia or MS, should i get the covid vaccine?

If I have cancer, dementia or MS, should i get the covid vaccine?

Infusion of convalescent blood plasma benefits patient with severe COVID-19

Infusion of convalescent blood plasma benefits patient with severe COVID-19

MDC researchers develop a potent weapon against lymphomas

MDC researchers develop a potent weapon against lymphomas

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Combination of venetoclax and standard therapies shows promise in high-risk myeloid blood cancers

Combination of venetoclax and standard therapies shows promise in high-risk myeloid blood cancers

Grants give military veterans better access to cancer clinical trials

Grants give military veterans better access to cancer clinical trials

Commonly prescribed anti-depressant may halt the growth of childhood sarcoma

Commonly prescribed anti-depressant may halt the growth of childhood sarcoma

Case study reports prolonged infectious SARS-CoV-2 shedding from an asymptomatic leukemia patient

Case study reports prolonged infectious SARS-CoV-2 shedding from an asymptomatic leukemia patient

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.